# OnCo record advanced-melanoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/advanced-melanoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "advanced-melanoma" ;
  schema:name "Advanced melanoma (unresectable stage III and stage IV)"@en ;
  schema:alternateName "Metastatic melanoma"@en, "Stage IV melanoma"@en, "Unresectable melanoma"@en, "First-line advanced melanoma"@en ;
  schema:description "Advanced melanoma has spread beyond what surgery can remove, and it is the cancer in which immunotherapy first proved it could cure some people: about half of those given nivolumab with ipilimumab are alive ten years later. If immunotherapy fails, options include a cell therapy grown from the patient's own immune cells, a virus injected into the tumour, and targeted pills for BRAF-mutant disease."@en ;
  schema:url <https://onco.cc/cancers/advanced-melanoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Melanoma> ;
  schema:citation <https://www.nejm.org/doi/full/10.1056/NEJMoa2407417>, <https://www.annalsofoncology.org/article/S0923-7534(24)03910-3/fulltext>, <https://www.nejm.org/doi/full/10.1056/NEJMoa2210233>, <https://en.wikipedia.org/wiki/Melanoma> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/secondary-brain-tumours/>, <https://onco.cc/cancers/braf-v600-melanoma/>, <https://onco.cc/cancers/uveal-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/til-therapy/>, <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/lag3-blockade/>, <https://onco.cc/technologies/tcr-t/>, <https://onco.cc/technologies/radiosurgery-srs/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/kit/>, <https://onco.cc/targets/prame/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/talimogene-laherparepvec/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/aldesleukin/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/fixed-duration/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/checkmate-067/>, <https://onco.cc/trials/relativity-047/>, <https://onco.cc/trials/keynote-006/>, <https://onco.cc/trials/dreamseq/>, <https://onco.cc/trials/checkmate-204/>, <https://onco.cc/trials/c-144-01/>, <https://onco.cc/trials/combi-d/>, <https://onco.cc/trials/cobrim/>, <https://onco.cc/trials/columbus/> ;
  onco:people <https://onco.cc/people/jedd-wolchok/>, <https://onco.cc/people/james-larkin/>, <https://onco.cc/people/caroline-robert/>, <https://onco.cc/people/hussein-tawbi/>, <https://onco.cc/people/f-stephen-hodi/>, <https://onco.cc/people/michael-postow/>, <https://onco.cc/people/antoni-ribas/> ;
  onco:pipeline <https://onco.cc/trials/fianlimab-phase3-melanoma/>, <https://onco.cc/drugs/fianlimab/>, <https://onco.cc/trials/prism-mel-301/>, <https://onco.cc/drugs/brenetafusp/>, <https://onco.cc/trials/nct06743126/>, <https://onco.cc/drugs/ima203/>, <https://onco.cc/trials/nct05727904/>, <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/technologies/fmt-checkpoint-nonresponders/>, <https://onco.cc/trials/nct05155254/>, <https://onco.cc/drugs/io102-io103/>, <https://onco.cc/trials/nct06697301/>, <https://onco.cc/drugs/eik1001/>, <https://onco.cc/trials/seacraft-2/>, <https://onco.cc/trials/nct06008106/>, <https://onco.cc/drugs/tunlametinib/>, <https://onco.cc/trials/nct05625399/> ;
  onco:standardOfCare <https://onco.cc/trials/checkmate-067/>, <https://onco.cc/trials/relativity-047/>, <https://onco.cc/trials/keynote-006/>, <https://onco.cc/trials/dreamseq/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/cancers/braf-v600-melanoma/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/trials/columbus/>, <https://onco.cc/trials/combi-d/>, <https://onco.cc/trials/cobrim/>, <https://onco.cc/trials/checkmate-204/>, <https://onco.cc/cancers/secondary-brain-tumours/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/trials/c-144-01/>, <https://onco.cc/technologies/til-therapy/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/trials/keynote-006/>, <https://onco.cc/terms/fixed-duration/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/technologies/isolated-limb-perfusion/> .